Title | Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Scott, BL, Pasquini, MC, Fei, M, Fraser, R, Wu, J, Devine, SM, Porter, DL, Maziarz, RT, Warlick, E, Fernandez, HF, Soiffer, RJ, Alyea, E, Hamadani, M, Bashey, A, Giralt, S, Geller, NL, Leifer, E, Hourigan, CS, Gui, G, Mendizabal, A, Horowitz, MM, H Deeg, J, Horwitz, ME |
Journal | Transplant Cell Ther |
Volume | 27 |
Issue | 6 |
Pagination | 483.e1-483.e6 |
Date Published | 2021 06 |
ISSN | 2666-6367 |
Keywords | Adolescent, Adult, Aged, Diterpenes, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Prospective Studies, Transplantation Conditioning, Transplantation, Homologous, Young Adult |
Abstract | Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with |
DOI | 10.1016/j.jtct.2021.02.031 |
Alternate Journal | Transplant Cell Ther |
PubMed ID | 33775615 |
PubMed Central ID | PMC8217373 |
Grant List | U10 HL069294 / HL / NHLBI NIH HHS / United States UG1 HL069290 / HL / NHLBI NIH HHS / United States U01 HL069274 / HL / NHLBI NIH HHS / United States U10 HL069274 / HL / NHLBI NIH HHS / United States UG1 HL108987 / HL / NHLBI NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States UG1 HL069274 / HL / NHLBI NIH HHS / United States UG1 HL138658 / HL / NHLBI NIH HHS / United States U24 CA076518 / CA / NCI NIH HHS / United States U24 HL138660 / HL / NHLBI NIH HHS / United States |